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ABSTRACT:  
Transplantation of human muscle precursor cells (hMPCs) is envisioned for the 
treatment of various muscle diseases. However, a feasible non-invasive tool to 
monitor cell survival, migration and integration into the host tissue is still 
missing. Methods: In this study, we designed an adenoviral delivery system to 
genetically modify hMPCs to express a signaling-deficient form of a human 
dopamine D2 receptor (hD2R). The gene expression levels of the receptor were 
evaluated by Reverse Transcriptase Polymerase Chain Reaction (RTPCR) and 
infection efficiency was visualized by fluorescent microscopy. Viability, 
proliferation and differentiation capacity of the transduced cells were confirmed 
and their sustained myogenic phenotype was shown by flow cytometry analysis 
and fluorescent microscopy. 18F-Fallypride and 18F-FMISO, two well-
established PET radioligands, were successfully synthesized and evaluated for 
their potential to image engineered hMPCs in a mouse model. Furthermore, 
biodistribution studies and autoradiography were also performed to determine 
the extent of signal specificity. Results: To address the feasibility of the 
presented approach for tracking of hMPCs in an in vivo model, we first 
evaluated the safety of the adenoviral gene-delivery, which showed no 
detrimental effects on the primary human cells. Specific binding of 18F-
Fallypride to hD2R_hMPCs was demonstrated in vitro, as well as in vivo, by 
performing autoradiography, biodistribution and PET experiments, respectively. 
Furthermore, 18F-FMISO uptake was evaluated at different time-points after 
cell inoculation in vivo, showing high signal only at the early stages. Finally, 
histological assessment of the harvested tissues confirmed the sustained 
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survival of the transplanted cells at different time-points with formation of 
muscle tissue at the site of injection. Conclusion: We here propose a signaling-
deficient human D2R as a potent reporter for in vivo hMPCs PET tracking by 
18F-Fallypride. This approach is a significant step forward towards a potential 
non-invasive tracking of hMPC_hD2R cells and bioengineered muscle tissues in 
the clinic.  
 
Key Words: human muscle precursor cells, dopamine 2 receptor, hypoxia, in 
vivo imaging, PET 
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INTRODUCTION 
To date, organ transplantation is the gold standard for rescuing damaged 
tissues. This method comes with a number of drawbacks such as dependence 
on donor organs and the high morbidity of immunosuppressive therapy. 
Regenerative medicine using autologous stem cells may offer an alternative 
approach for organ and tissue replacement, overcoming the known pitfalls(1-3). 
Tissue engineering, a major regenerative medicine component, follows the 
principles of cell transplantation, materials science, and engineering towards the 
development of biological substitutes that can restore and maintain normal 
function(4). Due to their regenerative capacity, MPCs are investigated for 
skeletal muscle tissue reconstruction and replacement(5). These adult stem 
cells reside on muscle fibers periphery, where they are activated after injury, 
proliferating, differentiating into myoblasts and later fusing to form new 
myofibers, thereby granting sufficient progeny for repetitive tissue repair(6). The 
majority of MPCs are committed to the myogenic lineage and are therefore the 
most suitable source for muscle engineering(7). Recent preclinical studies have 
shown that muscle reconstruction using MPCs is a promising and feasible 
therapy(8), however, the fate of the cells after implantation still needs to be 
further investigated.  
Currently, these issues are addressed by histological assessment, which has 
one major shortcoming: the invasiveness of biopsies and bioengineered muscle 
tissue destruction. Novel non-invasive imaging technologies are therefore 
needed.  
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Molecular imaging is an emerging field, providing essential information about 
heterogeneous human disorders. While bioluminescence has very poor spatial 
resolution and magnetic resonance imaging lacks the high sensitivity of 
radionuclide-based tools, PET/CT is a system with both high resolution and high 
sensitivity(9). Although imaging reporter genes are available for fluorescence, 
bioluminescence and magnetic resonance imaging, only radionuclide-based 
reporter genes are currently investigated for use in patients(10-12). One such 
system is based on the D2R imaging using PET. Natively, the D2R expression 
is largely limited to the striata nigra brain region(13). A large number of specific 
and high-affinity D2R PET ligands are available, some of which have found 
routine application in the clinic(14). Thus, the PET imaging of exogenously 
added hD2R in cells injected in peripheral body regions would be an attractive 
method to track the hD2R in vivo. One potential shortcoming of this approach, 
however, is the possible induction of undesired biological effects by gene 
introduction and by alteration of intracellular signalling pathways. As binding of 
the D2R ligand would activate G-protein-linked signalling pathway, a mutated 
rat receptor (D2R80A) has been reported, that uncouples ligand binding from 
intracellular signal transduction(15),(16). However, there are limits to the 
amount of signal production, as one receptor interacts with only one ligand 
molecule and can potentially be blocked by non-labelled endogenous 
ligands(17). 
Skeletal muscle cells are a key target for many stem cell and gene therapy 
applications. With PET imaging gaining increasing importance in regenerative 
medicine, it is of high interest to study transfected MPCs as cell types that could 
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be used to restore muscle function. In this study, we investigated the possibility 
of using PET/CT imaging to non-invasively monitor implanted and genetically 
modified hMPCs_hD2R in a mouse model. Specifically, our main aim was to 
study the location, level of expression and survival duration of the engineered 
hMPCs using hD2R as a reporter gene. The accomplishment of this goal would 
help to improve our understanding of the behaviour of hMPCs during in vivo 
differentiation.  
 
MATERIALS AND METHODS  
Isolation and Expansion of hMPCs 
Human muscle biopsies from Musculus rectus abdominis were randomly 
collected after approval by the local institutional review board and after written 
informed consent of hospitalized patients undergoing abdominal surgery. All 
samples were processed according to established protocols(18).  
 
Adenoviral Design 
The AdEasy System (Stratagene(19)) was used for recombinant adenovirus 
construction. Briefly, we mutated phenylalanine 411 of the hD2R into alanine 
(F411A) to obtain a signalling-deficient hD2R that still binds ligands in a normal 
manner but will not activate intracellular signalling upon ligand binding(20). In 
detail, IRAUp969E0451D vector containing hD2R (ImaGenes) and pcDNA3 
plasmid containing monomer red fluorescent protein (m)RFP (Addgene) were 
purchased. The hD2R was subcloned into the pcDNA3.1 TOPO expressional 
vector (Invitrogen), which resulted in addition of C-terminal 6xHis and V5 tags. 
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Next, the F411A point-mutation was introduced by site-directed-mutagenesis 
(Stratagene). The hD2R and mRFP sequences were then subcloned into the 
backbone of the pShuttle-cytomegalovirus vector (Addgene), ensuring a robust, 
constitutive expression. The final vector thus contained hD2R and RFP 
sequences, both running under two separate cytomegalovirus promoters. 
Successful cloning was validated by sequencing, while viral infection and gene 
expression were monitored by visualizing RFP and RTPCR, respectively. The 
transduced cells were expanded for 2 days after infection and were 
subcutaneously (s.c.) injected into nude mice.  
 
Cell Viability and Proliferation 
In all cases, cell numbers and viability were confirmed by trypan blue staining. 
To evaluate proliferation and viability of the infected cells at different time 
points, hMPCs were cultured for 6 days. The cell proliferation reagent WST-1 
(Roche) was used according to manufacturer’s protocol. For further 
confirmation of cell viability, hMPCs were stained with 10 μM CellTrace Calcein 
green, AM (Life Technologies), 30min, 37 °C. Viable cells were detected using a 
fluorescence microscope. All measurements were repeated at least three times 
and samples were analyzed in triplicates. 
 
Radiosynthesis of 18F-Fallypride 
The synthesis of 18F-Fallypride was accomplished in a one-step reaction 
according to a published procedure(21). The radiotracer was obtained in 
radiochemical purity >95% and specific activity ranged from 32-168 GBq/μmol. 
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Radiosynthesis of 18F-FMISO 
18F-FMISO was obtained in a two-step reaction in analogy to a previously 
published method(22). The final formulated product was obtained in a decay 
corrected radiochemical yield ranging from 25-37%. Radiochemical purity was 
>95% and specific activities ranged from 34-190GBq/μmol. 
 
In vitro 18F-Fallypride Uptake assay 
The experiment was performed in longitudinally truncated 24-well-plates testing 
two AV-hD2R constructs in three concentrations (500ng, 1μg, 2μg/well). 
Approximately 20`000 hMPCs/well were seeded and after 24h the cells were 
infected with the corresponding constructs for 2 days. The modified cells were 
incubated with 18F-Fallypride [1nM] for 15 min and scanned 26 min after start 
of incubation. The cells were imaged using small animal PET scanner. The 
scan duration was 45 min. All experiments were performed in triplicates. 
 
Animal Experimentation 
All animal experiments were approved by the local animal care committee. A 
total of 46 female, 8 week old nude mice (Charles River) were used for this 
study. The hMPCs were expanded to passage 3-4 for the in vivo experiments. 
Each sample contained 30x106 transduced hMPCs, which were gently mixed 
with 500μL collagen type I carrier (final concentration: 2mg/mL) (BD) and 
prepared for s.c. injection in the back of nude mice(23). Each animal received 
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two bilateral s.c. injections (including control-collagen only injections). The 
engineered skeletal muscle tissues were harvested after 1, 2, and 4 weeks.  
 
Tracking of Bioengineered Muscle Tissues via PET/CT Imaging 
PET experiments were performed with a dedicated small animal PET/CT 
tomograph eXplore VISTA (General Electric), which uses the phoswich detector 
technology in a dual ring set-up(24). For 18F-Fallypride administration, mice 
were restrained and injected via a lateral tail vein with 4.38-26.25MBq (0.17-
2.34nmol) of the radioligand. For blockage experiments, Haloperidol (1mg/kg) 
was injected. Ten minutes after radiotracer injection, animals were anesthetized 
with isoflurane in air/oxygen mixture, positioned and fixed on the bed of the 
camera. PET data were acquired to yield dynamic images with sufficient count 
statistics. Depth of anesthesia and body temperature were monitored and 
controlled according to a previously published protocol(25). In addition, 
respiratory frequency was controlled with 1025T monitoring system from SA 
Instruments (Stony Brook, NY). After the PET scan, animals recovered from 
anesthesia and were rescanned at a later time point with the next tracer. Raw 
data were reconstructed by 2D-OSEM algorithm and the obtained image data 
were evaluated by visual inspection and semi-quantitative volume-of-
interest(26) analysis using the dedicated software PMOD. 
 
Biodistribution Studies 
The subsequent post-mortem biodistribution assessment was performed 60 min 
post i.v. injection of 18F-Fallypride. Tracer uptake in engineered muscle tissue, 
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striatum nigra, native muscle tissue, cerebellum and injected collagen was 
evaluated in a gamma-counter (CobraIIAuto-gamma, Canberra Packard, 
Groningen, Netherlands). 
 
Autoradiography 
Cryosections (20μm) of frozen samples were pre-incubated on ice for 12min in 
TRIS/HCl, 0.1% BSA, pH 7.4. Then, the slides were incubated with 18F-
Fallypride [0.03nM] in the presence and absence of Haloperidol [10μM] as 
blocker for 60min. After air-drying the tissue slices were exposed to 
phosphorimager plates which were analysed with Fuji BAS-5000 
phosphorimager. 
 
Histological Assessment 
The harvested engineered muscle tissues were embedded in cryo-preservative 
(OCT embedding medium, Cell Path) immediately after isolation. Cryosections 
were prepared (10μm) and further processed. Haematoxylin and eosin (H&E) 
(Sigma) staining was performed according to the manufacturer’s protocol.  
 
Statistics 
For statistical analysis IBM SPSS v22.0 (SPSS Inc,) was used and graphs were 
drawn with GraphPad Prism v5.04 (GraphPad Software, Inc.). All data were 
analysed by Student’s t-tests or one-way ANOVA with Bonferroni or LSD post-
hoc analysis (p<0.05 was considered significant). All presented data are 
expressed as means with corresponding standard error of the mean (±SEM). 
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RESULTS 
 
Viability, Proliferation and Differentiation Rates of Genetically Modified 
hMPC_hD2R 
The adenoviral construct containing hD2R (F411A) was generated and 
amplified for further use in hMPCs. Non-toxicity of the viral infection was 
visualized by a cell viability assay (calcein) (Fig.1A, green), where no significant 
differences between WT and hD2R-infected cells were detected. The 
transduction efficiency of ~25% infected cells was confirmed by fluorescent 
imaging, as the designed construct contained a red fluorophore, expressed 
under a separate cytomegalovirus promoter (Fig.1A, red). This construct 
allowed assessment of cell transduction efficiency prior to transplantation. Using 
a fiber formation assay(27), we evaluated the capability of hMPCs to form 
myofibers in vitro (Fig.1A, third row). Comparison between WT and hD2R-
overexpressing cells (Supplemental Fig.1) did not reveal any significant 
difference in the number of nuclei per fiber (p=0.8629, WT: 8.325±0.6818, n=83; 
hD2R: 8.184±0.4635, n=87), number of nuclei per high-power-field (WT: 
230.6±14.34, n=10; hD2R: 216.9±10.71, n=10, p=0.4539) and the number of 
fibers per high-power-field (WT: 8.3±0.8699, n=10; hD2R: 8.4±0.5812, n=10, 
p=0.9249). The calculated overall fusion did not differ between infected and WT 
cells either (WT: 30.95±3.289, n=10; hD2R: 32.40±3.085, n=10, p=0.7512). 
Successful transduction was also confirmed by hD2R gene expression levels 
(Fig.1B, n=3x3, p=0.005). Furthermore, proliferation capacity of the WT and 
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hD2R-overexpressing hMPCs was determined by cell proliferation assay over 3 
days culturing following transduction, showing no significant variations between 
the different groups (Fig.1C, WT: 2.2173±0.364, n=6; hD2R: 2.0843±0314, n=6, 
p=0.787 at 3 days).  
 
Flow Cytometry and Immunocytochemistry Analysis of hMPC_hD2R 
Initially, the cells were analyzed by immunocytochemistry (Fig.2A), and in 
parallel by flow cytometry (Fig.2B) 2 days after infection, revealing a sustained 
muscle phenotype without significant alterations between the groups. 
 
In Vitro PET/CT Imaging of hMPC_hD2R Using 18F-Fallypride 
Before each experiment, the infection efficiency was assessed by fluorescent 
microscopy and positive cells were further processed for in vitro or in vivo 
studies. Initially, the capacity of the transduced hMPCs_hD2R to efficiently bind 
18F-Fallypride was evaluated in vitro. When using the designed adenovirus, 
testing 3 different concentrations of viral particles for tracer uptake, we 
observed a high binding affinity (Fig.3A). As expected, the cells infected with the 
highest non-toxic concentration showed the highest detectable PET signal (first 
row, 10x) and were thus used for further experiments. These data confirm the 
efficiency of the presented hD2R adenoviral construct for hMPCs genetic 
modification. 
 
In Vivo PET/CT Imaging of hMPC_hD2R Using 18F-Fallypride 
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Encouraged by our in vitro results, we evaluated the capability of transduced 
hMPCs to specifically bind 18F-Fallypride in an established ex situ model for 
skeletal muscle tissue formation in vivo. The hMPC_hD2R showed high 
standardized uptake value (SUV) after 1 week (SUV: 0.259±0.019, n=8). This 
signal decreased after two weeks (SUV: 0.169±0.019, n=8, p=0.005) and no 
significant difference to background was observed after 4 weeks (SUV: 
0.134±0.014, n=6, p<0.0001) (Fig.3B). Animals injected with collagen only did 
not show a significant radiotracer accumulation at any time (SUV: 0.115±0.011, 
n=10). Cerebellum brain region was used as negative control, showing 
negligible non-specific uptake (SUV: 0.124±0.006, n=16). This was confirmed 
by VOI (26) analysis, where significantly higher signal-to-background ratio of at 
least 2.08 at the earliest time point was observed (Fig.3B). Biodistribution 
assessment also showed significant decrease in tracer uptake in engineered 
tissues over time (Fig.4A, n=4-16 per time point). Signal specificity was 
demonstrated in in vivo PET studies using haloperidol as D2R blocking agent; 
the striatum region was visualized as positive control (Fig.4B). Additionally, 
radioligand binding specificity was demonstrated in autoradiography studies, 
whereby hD2R-expressing tissues (including native controls) showed reduction 
of radioligand uptake after incubation with haloperidol (Fig.4C), confirming the in 
vivo data. 
 
PET Imaging of Hypoxia Using 18F-FMISO during Formation of 
Bioengineered Skeletal Muscle Tissue 
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After successful tracking of the injected hMPC_hD2R, we were further 
interested in studying the oxygenation status of the cells after implantation. To 
address this we utilized 18F-FMISO, a PET radiotracer for visualizing hypoxic 
regions. One week after cell inoculation, a relatively high 18F-FMISO uptake 
was observed which decreased at later time points (Fig.5A). VOI analysis of the 
first week samples (SUV: 0.315±0.02, n=8) showed a mean signal change ratio 
of 1.6, compared to later time points (2wk: SUV: 0.189±0.019, n=8; 4wk: SUV: 
0.205±0.009, n=6) and negative controls (cerebellum: SUV: 0.206±0.017, n=16; 
collagen: SUV: 0.251±0.003, n=10 (Fig.5B)). 
 
Histological Assessment, Gene and Protein Analysis of the Harvested 
Tissues 
The relative protein expression of typical skeletal muscle protein markers 
(sarcomeric α-actinin, MyHC), vWf and hD2R were evaluated after tissue 
harvest by Western Blot (Fig.6A). Tibialis anterior (TA) and striatum nigra (SN) 
were used as controls. The protein expression levels of sarcomeric markers 
gradually increased in the bioengineered tissue samples (MyHC: 0.4211±0.033, 
n=4 (1wk); 2.1915±0.407, n=6 (2wk); 3.0734±0.72, n=8 (4wk), p=0.012, 
respectively; α-actinin: 0.4065±0.111, n=4 (1wk); 0.6734±0.113, n=6 (2wk); 
1.2696±0.315, n=8 (4wk), p=0.043, respectively), corresponding to the 
expected timeline of muscle fiber formation (Fig.6A). The relative hD2R protein 
expression decreased steadily over time (2.4072±0.608, n=3 (1wk); 
1.5881±0.25, n=6 (2wk); 1.0394±0.294, n=12 (4wk), p=0.031, respectively) 
(Fig.6A), concomitant with the observed decrease of 18F-Fallypride uptake 
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(Fig.3B). The decrease in 18F-FMISO uptake over time coincided with an 
increase in vWf protein levels (endothelial cell marker, n=4) (Fig.6A), as well as 
with a rising vascular endothelial growth factor (VEGF-A) gene expression 
(Supplemetal Fig.2B, n=9) in the bioengineered muscle tissues. Although hD2R 
protein levels were decreasing over time, the corresponding gene expression 
levels were increasing (Supplemental Fig.2B). The gradual decrease in size due 
to collagen remodeling and myofiber formation has previously been 
reported(23) (Supplemental Fig.2A). Histological analysis revealed successful 
myofiber formation in the harvested tissues and could illustrate the individual 
cells of the samples at week 1 and the myotube formation at week 2 and 4 
(Fig.6B). 
 
DISCUSSION 
Transplantation of MPCs has been considered as a treatment option for 
genetic and acquired muscle disorders(23, 28) and provides a prospect to 
reestablish damaged muscle function in patients with muscle degeneration(29). 
Various research groups demonstrated the formation of muscle tissue after 
cellular inoculation(30). However, the long-term non-invasive tracking of 
bioengineered muscle tissue has not been addressed so far.  
The need to develop a system combining the use of well-established 
PET probes and the engineering of a novel vector for expression of the hD2R in 
hMPCs has prompted our research towards non-invasive visualization of a cell 
therapy for application in skeletal muscle bioengineering. The generation of a 
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vector coding for a signaling-deficient hD2R was an important milestone as 
redundant cell-signaling is a major issue in gene therapies.  
In this study, we describe a method for metabolic imaging and tracking of 
hMPCs using PET/CT, thereby illustrating their exact position and the 
oxygenation state of the newly formed skeletal muscle tissue over time. The 
results of our studies indicated that: 1) the signaling-deficient hD2R could be 
efficiently introduced into primary hMPCs, 2) no detrimental effects on cell 
viability and differentiation were detected, 3) myogenic marker gene expression 
was unaltered, 4) the receptor was traceable with high specificity using 18F-
Fallypride both in cells in vitro as well as after injection in vivo and 5) receptor 
expression in the engineered tissues could be validated by autoradiography. 
We found that the capacity to track the hD2R_hMPCs is excellent in the first 
week and declines later on. Interestingly, while mRNA expression of hD2R 
remained high, its protein levels steadily declined. This indicates that the 
ectopically expressed hD2R is either post translationally modified and/or 
internalized upon constitutive expression and ultimately degraded during the 
process of final differentiation to myofibers. Our data showed that by using a 
high-affinity PET ligand and a mutated hD2R we were able to provide important 
information on localization, survival and metabolic features for the early phase 
after cell injection. 
A general problem in tissue engineering approaches is the increased 
oxygen demand and lack of initial vascularization during the early phases of 
tissue formation, leading to central necrosis(31). Any engineered tissue larger 
than 0.3 cm3 requires rapid vascularization to guarantee survival of cells located 
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within the core of the construct. Vascularization of bioengineered tissue is 
therefore a bottle-neck. Hypoxia, which is inversely proportional to the degree of 
vascularization can be analysed by invasive and non-invasive methods in 
tissues. The oxygenation status of cells and tissues can be determined by 
invasive pO2-measurements using polarographic needle electrodes or with 
fiber-optic probes(32-34). Non-invasive methods include the use of bio-
reductive chemical markers, such as 2-nitroimidazoles(35). They form adducts 
under hypoxic conditions and are irreversibly bound in hypoxic cells. 18F-
FMISO is the most widely used PET radioligand for imaging hypoxia in 
humans(36-38). 
In our study with 18F-FMISO, we detected metabolically active 
bioengineered tissues with low oxygen levels, i.e. where reductive reactions 
dominate due to low oxygen supply or high oxygen consumption, typical for the 
early stages of cell-to-myofiber formation. It has been shown that the level of 
oxygenation is influenced by the degree of vascularization and by the metabolic 
consumption of oxygen by engineered tissue(39). Concomitant with our in vivo 
observations, increased VEGF release in a hypoxic environment has been 
shown to lead to enhanced differentiation(40). Histological analysis confirmed 
the cell-to-myofiber transition, correlating with normalized vascularization levels. 
In line with these observations, using 18F-FMISO for hypoxia imaging of 
bioengineered constructs seems to be a feasible method.  
 
CONCLUSION 
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Knowledge of the fate of the inoculated primary hMPCs is a prerequisite 
for future clinical implementation of this cell therapy. Combining the recent 
developments in designing robust vectors and novel highly-specific PET 
imaging probes, we were able to offer an elegant solution, obviating the need 
for a destructive tissue biopsy. Our study marks a significant step forward 
towards the non-invasive tracking of hMPC_hD2R cells and bioengineered 
muscle tissues in the clinic using PET. 
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Figure 1. hD2R adenoviral infection did not show adverse effects on 
hMPC. The adenoviral transduction of hMPCs with hD2R did not affect the cell 
viability (A, calcein assay, first row, green). Transduction efficiency was shown 
by fluorescence microscopy (A, second row, red). The ability to form fibers was 
also not affected by the virus (A; third row). The hD2R gene expression was 
evaluated (B). Proliferation rate did not differ between WT non-infected and 
infected hMPCs (C). All measurements were performed in duplicates from at 
least 3 different biopsies. (Student’s t-test, *p<0.05). CaAM: calcein AM; FFA: 
fiber-formation-assay; RFP: red-fluorescent-protein; WT: wild type  
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Figure 2. Adenoviral infection with hD2R did not change the well-defined 
hMPC phenotype. Expression of typical muscle markers (green) in the cells 
expressing hD2R (red) was confirmed by immunocytochemistry. Nuclei are 
shown in blue (A). The hMPCs were further analyzed by flow cytometry (B). 
Scale bar: 25μm. (Student’s t-test, *p<0.05, n=4 biopsies).  
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Figure 3. Tracking of hMPCs and engineered muscle tissue via PET/CT 
using 18F-Fallypride in vitro and in vivo. 18F-Fallypride uptake in 
hMPC_hD2R was detected at different adenoviral hD2R transduction levels (A). 
In vivo PET/CT imaging visualized specific tracer uptake in bioengineered 
tissues over time and VOI analysis illustrated gradual decrease in signal after 
1wk (B, n=6-8). SUV: standardized uptake value, VOI: volume-of-interest. 
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Figure 4. Specificity of 18F-Fallypride signal. Significant enhancement of 
18F-Fallypride uptake in engineered hMPC_hD2R tissue, compared to collagen 
and control muscle was observed in a biodistribution study (A, n=4-16). Tracer 
specificity was evaluated after blockage experiment with Haloperidol (B). 
Autoradiography showed specific tracer binding (C, lane 1). Blockage was 
performed with Haloperidol (lane 2) and mouse muscle and rat brain sections 
were used as negative and positive controls, respectively. Images were 
averaged from 60 – 120 min. Arrows indicate hMPCs injection site. (one-way 
ANOVA with Bonferroni post-hoc analysis, *p<0.05), SUV: standardized uptake 
value   
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Figure 5. Hypoxia PET/CT monitoring with 18F-FMISO during formation of 
bioengineered muscle tissues. The redox state of the forming tissues was 
illustrated with 18F-FMISO [injected activity: 0.49-5.86nmol, 14.86-35.83MBq] 
(A) and VOIs signal was calculated for 3 different time points (B). Images were 
averaged from 90–110 min. Arrows indicate hMPCs injection sites. 
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Figure 6. Protein expression levels were evaluated by Western Blot (A): vWf, 
MyHC, sarcomeric α-actinin and hD2R expression changes were visualized 
graphically. H&E staining revealed increasing fiber formation capacity over time 
(B). Tibialis anterior (TA) was used as a control. Scale bar: 100µm (one-way 
ANOVA with Bonferroni or LSD post-hoc analysis, *p<0.05)  
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